Mostrar el registro sencillo del ítem

dc.contributor.authorGomez Rueda, Hugoen
dc.contributor.authorMartínez Ledesma, Emmanuelen
dc.contributor.authorMartínez Torteya, Antonioen
dc.contributor.authorPalacios Corona, Rebecaen
dc.contributor.authorTreviño, Victoren
dc.date.accessioned2016-06-20T03:09:16Z
dc.date.available2016-06-20T03:09:16Z
dc.date.issued29/10/2005
dc.identifier.otherBioData Mining
dc.identifier.urihttp://hdl.handle.net/11285/613678
dc.description.abstractIn cancer, large-scale technologies such as next-generation sequencing and microarrays have produced a wide number of genomic features such as DNA copy number alterations (CNA), mRNA expression (EXPR), microRNA expression (MIRNA), and DNA somatic mutations (MUT), among others. Several analyses of a specific type of these genomic data have generated many prognostic biomarkers in cancer. However, it is uncertain which of these data is more powerful and whether the best data-type is cancer-type dependent. Therefore, our purpose is to characterize the prognostic power of models obtained from different genomic data types, cancer types, and algorithms. For this, we compared the prognostic power using the concordance and prognostic index of models obtained from EXPR, MIRNA, CNA, MUT data and their integration for ovarian serous cystadenocarcinoma (OV), multiform glioblastoma (GBM), lung adenocarcinoma (LUAD), and breast cancer (BRCA) datasets from The Cancer Genome Atlas repository. We used three different algorithms for prognostic model selection based on constrained particle swarm optimization (CPSO), network feature selection (NFS), and least absolute shrinkage and selection operator (LASSO).
dc.language.isoengen
dc.publisherOpen Access Publisheren
dc.relation.ispartofseriesSurvivalen
dc.relation.ispartofseriesCanceren
dc.relation.ispartofseriesGenomicsen
dc.relation.ispartofseriesTCGAen
dc.relation.urlhttps://biodatamining.biomedcentral.com/articles/10.1186/s13040-015-0065-1en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleIntegration and comparison of different genomic data for outcome prediction in canceren
dc.typeArtículo / Articleen
dc.contributor.departmentTecnologico de Monterreyen
dc.subject.disciplineCiencias de la Salud / Health Sciences
refterms.dateFOA2018-03-18T23:35:38Z
html.description.abstractIn cancer, large-scale technologies such as next-generation sequencing and microarrays have produced a wide number of genomic features such as DNA copy number alterations (CNA), mRNA expression (EXPR), microRNA expression (MIRNA), and DNA somatic mutations (MUT), among others. Several analyses of a specific type of these genomic data have generated many prognostic biomarkers in cancer. However, it is uncertain which of these data is more powerful and whether the best data-type is cancer-type dependent. Therefore, our purpose is to characterize the prognostic power of models obtained from different genomic data types, cancer types, and algorithms. For this, we compared the prognostic power using the concordance and prognostic index of models obtained from EXPR, MIRNA, CNA, MUT data and their integration for ovarian serous cystadenocarcinoma (OV), multiform glioblastoma (GBM), lung adenocarcinoma (LUAD), and breast cancer (BRCA) datasets from The Cancer Genome Atlas repository. We used three different algorithms for prognostic model selection based on constrained particle swarm optimization (CPSO), network feature selection (NFS), and least absolute shrinkage and selection operator (LASSO).


Ficheros en el ítem

Thumbnail
Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

http://creativecommons.org/licenses/by-nc-nd/4.0/
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by-nc-nd/4.0/